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Abstract 
 
Background: The short version of the Problem Behaviours Assessment (PBA-s) is the 
UHFRPPHQGHGRXWFRPHPHDVXUHIRUEHKDYLRXUDOV\PSWRPVLQ+XQWLQJWRQ¶VGLVHDVH5DVFK
analysis was used to further investigate the measurement limitations of the PBA-s. 
Objectives: 1) To assess the psychometric properties of the 11 severity and frequency items 
within the PBA-s and 2) to determine the construct validity of using a total PBA-s score as a 
clinical outcome measure. 
Methods: PBA-s data for 517 participants from Enroll-HD were included in the Rasch analysis. 
Separate analyses were conducted for the severity and frequency items of the PBA-s, using 
RUMM2030 software. Achieving fit to the model provides supporting evidence that all items 
contribute to a single underlying latent trait. This property is defined as internal construct 
validity.  
Results: The total PBA-s severity score demonstrated several important limitations, including 
disordered response categories for all 11 severity items, local dependency and poor targeting. 
However, modifying the original five-point scoring system to a four-point system resulted in 
ordered response categories for seven of the severity items and achieved a good overall fit to 
the Rasch model. For the total PBA-s frequency score, fit to the model was not achieved even 
after amendments to the scoring system.  
Conclusions: This study suggests that with reduction to a four-point scoring system, the total 
PBA-s severity score may be considered a valid clinical outcome measure. This study also 
suggests limitations in the use of a total PBA-s frequency score. 
 
 
Keywords: 5DVFK3V\FKRPHWULFV+XQWLQJWRQ¶VGLVHDVH3UREOHP%HKDYLRXUV
Assessment, Enroll-HD 
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Introduction 
+XQWLQJWRQ¶V GLVHDVH +' LV DQ DXWRVRPDO GRPLQDQW QHXURGHJHQHUDWLYH GLVRUGHU
characterised by the development of debilitating motor, cognitive and behavioural symptoms 
[1]. The genetic defect responsible for HD is an unstable and extended CAG repeat length on 
the gene that encodes huntingtin, located on chromosome 4 [2]. In the Western world, the 
prevalence of HD is 4-12 per 100,000 and onset usually occurs insidiously in the fourth or fifth 
decade of life [3,4]. Behavioural (neuropsychiatric) symptoms in HD have been reported to 
have a greater impact on quality of life [5] and functional disability [6] than either cognitive or 
motor symptoms. These manifestations may develop many years before the onset of 
distinctive motor signs and are increasingly recognised as the main reason for 
institutionalisation, due to the disabling and distressing impact they have on both patients and 
their carers [6-8], making their early recognition vital.  
A wide range of behavioural symptoms have been recognised in HD, most commonly 
depression, irritability, apathy and anxiety which occur in up to seventy-six percent of patients 
[9]. Obsessive-compulsive behaviours, suicidal ideation and psychosis (hallucinations and 
delusions) occur less frequently. The short version of the Problem Behaviours Assessment 
(PBA-s) is a semi-structured interview containing 11 items, each designed to measure the 
severity and frequency of a different behavioural symptom in HD [1]. The PBA-s was developed 
by the EHDN Behavioural Working Group from an original 40-item version (PBA-HD), however, 
the shorter interview is more commonly used in clinical practice, as well as in multicentre RCTs 
and international observational studies such as REGISTRY and ENROLL-HD. In a recent 
systematic review it was identified as the recommended rating scale for behavioural symptoms 
in HD [10]. 
Traditionally, the method used for the development and evaluation of rating scales has 
been classical test theory (CTT) [11]. This approach focuses mainly on person-level statistics, 
such as means and standard deviations. CTT also uses test-level statistics such as &URQEDFK¶V
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alpha to assess reliability and factor analysis to determine the dimensionality of a 
measurement [12,13]. Factor analyses performed on the short and long version of the PBA 
have reported consistent findings, providing evidence to support its reliability from a traditional 
psychometric perspective [1,14,15].  
However, modern psychometric techniques such as Rasch analysis are increasingly 
adopted as a means to further investigate limitations in the use and interpretation of clinical 
outcome measures [16]. The Rasch approach provides an in-depth understanding of a rating 
VFDOH¶V PHDVXUHPHQW SURSHUWLHV DQG DOORZV IRU LGHQWLILFDWLRQ RI PHDVXUHPHQW LVVXHV QRW
detected by CTT analyses [17]. The Rasch measurement model applies the assumption that 
scores obtained for individual symptoms vary with respect to the overall severity of the trait 
being measured. For example, a person with more advanced behavioural symptoms would be 
more likely to score highly on items indicating a more severe clinical picture, such as suicidal 
ideation. The pattern of item responses in the sample data are tested against the expectations 
of the Rasch model. Achieving fit to the model provides supporting evidence that all items 
contribute to a single underlying latent trait, such as the overall severity of behavioural 
symptoms. This property is defined as internal construct validity [17,18].  
Rating scales are increasingly used as the primary outcome measure in clinical trials 
for neurological diseases, making them the main dependent variables that influence decisions 
made about the efficacy of future treatments and patient care [19]. With recent advances 
towards disease-modifying agents for HD [20], Rasch analysis provides a platform for reducing 
the risk of type-1 and type-2 errors in trials due to poor quality rating scales. Improving the 
ability of the PBA-s to detect important symptom changes has the potential to influence the 
outcome of trials investigating the effectiveness of new treatments for the disabling and 
debilitating behavioural symptoms of HD. The Rasch model has been used to successfully 
evaluate other psychiatric rating scales, including the Hamilton Rating Scale for Depression 
[13], the Hospital Anxiety and Depression Scale [18] and the Beck Depression Inventory [21].  
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The aim of this study was to determine the validity of the PBA-V IRU +XQWLQJWRQ¶V
disease using Rasch analysis. More specifically, the analysis process aimed to 1) assess the 
psychometric properties of the 11 severity and frequency items within the PBA-s and 2) 
determine the construct validity of using a total PBA-s score as a clinical outcome measure. 
To our knowledge, this is the first study to perform Rasch analysis on the PBA-s.  
 
Materials and Methods  
Study design 
This study analysed retrospective anonymised data from Enroll-HD, an ongoing multicentre 
longitudinal observational study established primarily in Europe and North America to monitor 
disease progression. Access to the Enroll-HD database allowed for generalisation to an 
international population of HD patients, maximising the external validity and minimising the 
confounding effects of cultural and national differences in the presentation of behavioural 
symptoms assessed by the PBA-s [22].  
 
Participants 
Since Enroll-HD was established in July 2012, participants have been continuously recruited 
into the database. Participants were required to visit their respective site to gather data on 
motor, cognitive and behavioural symptoms at baseline. Eligible participants were asked to 
attend annual follow-up visits. Individuals with choreic movement disorders that were negative 
for the HD mutation were not eligible for inclusion in Enroll-HD.  
For this study, demographic data for participants recruited between July 2012 and 
January 2015 were obtained from Enroll-HD on age, sex and CAG repeat length. Participants 
with a positive HD genotype were eligible for inclusion in this study, defined by the presence 
of &$*UHSHDWV[23]. Subjects with a normal CAG repeat length of 27 or intermediate 
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repeat range of 27-35 were excluded from the study [24]. Participants with a positive HD 
genotype who had not yet met the motor-defined diagnostic criteria (premanifest HD), as 
judged by a qualified interviewer, were included alongside participants with motor signs 
(manifest HD). The premanifest HD group were included as neuropsychiatric symptoms can 
occur several years before the onset of motor signs [7,8]. Total Functional Capacity (TFC) 
score (0-13) was used to classify manifest HD participants into five categories, lower scores 
signifying greater functional impairment [25]. Additionally, participants with a CAG repeat 
length  55 were excluded from this study, as this is strongly correlated with juvenile 
+XQWLQJWRQ¶V GLVHDVH ZKLFK presents with a different phenotype [26]. No randomisation 
process was required for this study and all subjects that met the eligibility criteria were included 
in the sample population.  
Access to the Enroll-HD data was approved by the Enroll-HD Scientific Publication 
Review Committee. All sites were approved by local ethics committees in their respective 
countries, ensuring written informed consent was signed by willing participants that fully 
understood the requirements of inclusion in Enroll-HD. This study was granted ethical approval 
from the local Internal Ethics Review Committee, University of Birmingham.  
 
Assessment of neuropsychiatric symptoms 
The PBA-s is an 11-item semi-structured interview specifically designed to address the most 
common behavioural and psychiatric symptoms of HD [1]. Each item is structured to elicit 
information from the patient, in order to enable the interviewer to categorise the patient into 
one of five pre-defined rating categories relating to each behavioural symptom. The short 
version of the PBA is recommended in clinical practice and performed more commonly in 
comparison to the original 40-item interview [10].  
The five-point PBA-s rating scale (0-4) includes two subscales for severity and 
frequency (Table 1), modelled on the previously recommended behavioural section of the 
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Unified HXQWLQJWRQ¶VDisease Rating Scale (UHDRS) [27]. The PBA-s assesses symptoms 
over the past four weeks, improving the recall of events by patients and the accuracy of the 
interview in comparison to the behavioural section of the UHDRS, which attempted to rate 
behaviour over the previous six months [1]. Only assessments completed in English were 
included in this study to avoid any inconsistencies of how items perform in different languages. 
The PBA-s is conducted either in clinic or at home, ideally in the presence of a 
knowledgeable informant, for example a relative or paid carer. The informant and patient are 
given the opportunity to speak to the interviewer together and separately. Discussion with the 
informant may elicit additional insigKWLQWRWKHVXEMHFW¶Vbehaviours, which could not easily be 
obtained in their presence [28]. The trained interviewer is then required to make a clinical 
judgment with regard to each item score, taking all information and observations into account. 
For this study, only scores completed by qualified interviewers, in the presence of the subject 
and an informant, were used to achieve a high quality data set. The PBA-s has been shown to 
have substantial agreement in scores given by different interviewers, indicating a good inter-
rater reliability [15].   
 
Data analysis  
Descriptive statistics were used to display the clinical characteristics and demographics of the 
study population. 
The PBA-s data were analysed using RUMM2030 software [29] to investigate whether 
the pattern of item responses observed in the data matched the expectations of the Rasch 
measurement model [17]. All 11 severity item scores were summed together to create a total 
PBA-s severity score and the same method was used to produce a total PBA-s frequency 
score. Rasch analysis enabled the construct validity of these two total PBA-s scores to be 
evaluated. Separate analyses were carried out for the severity scale and the frequency scale, 
but the analytic procedure was replicated for each scale. 
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Due to the consistent polytomous structure (i.e. more than two response categories) of 
the PBA-s, the initial step in Rasch analysis was to conduct a likelihood ratio test. This 
determined which mathematical derivation of the Rasch model was more appropriate for the 
data set. A significant result for the likelihood ratio test (p<0.05) supports the use of the partial 
credit model [30] instead of the simpler rating scale model [31].  
The following fundamental aspects of Rasch analysis were assessed:  
1) Overall fit to the model: this was evaluated using the total chi-square item-trait 
interaction statistics for both the severity and frequency dimensions of the PBA-s [18,32]. A 
non-significant chi-square probability value gives an indication of a good level of overall fit, 
using a Bonferroni alpha value adjusted for the number of items [33]. The item-person 
interaction statistics summarise the individual item fit and person fit to the model. These 
standardised fit residual values approximate a z-score, and therefore a perfect fit would result 
in a mean value of 0 and a standard deviation of 1 [18]. These summary residual statistics 
(and the deviation from the perfect values) may give an overall impression of the fit, although 
these do not reveal specific item-level and person-level misfit.  
2) Adequacy of the response categories: threshold maps and category probability 
curves were examined to identify disordered thresholds as a potential cause of misfit [32]. A 
threshold is the point between two adjacent response categories when the probability of the 
UHVSRQGHQWHQGRUVLQJHLWKHURSWLRQLVHJHTXDOO\OLNHO\WRVFRUHD³´RUD³´ [12]. A 
disordered threshold indicates that a response category is never the most likely response, at 
any underlying level of the trait in question. This implies that the original response categories 
are not functioning as intended, and this may be due to a number of reasons [18], including 
that assessors find it difficult to differentiate between the various response categories for that 
particular item. When disordered response categories were encountered, categories were 
collapsed together and rescored to correct for the apparent disorder and improve fit to the 
model.  
Rasch analysis of the PBA-s   
             
9 of 50 
 
3) Individual item and person fit: standardised fit-residual values for items and persons 
were examined for any indication of misfit (values outside of ± 2.5). The residual value is the 
deviation from the Rasch model, summated for each individual item or person [18]. Individual 
item chi-square fit statistics were also assessed, using a Bonferroni-adjusted alpha-level.  
4) Local dependency: defined by the response to any one item being dependent on the 
response to any other item, after controlling for the underlying trait. To investigate local 
dependency between items, a residual correlation value of more than 0.2 above the average 
of all item residual correlations was considered indicative [34].  
5) Unidimensionality: to determine whether the scale was measuring a single 
unidimensional construct, principal component analysis (PCA) of the residuals was conducted 
to identify the two most different subsets of items (i.e. the most positively and negatively factor 
loading items on the first component). T-tests were performed comparing the scores on the 
two subsets of items for each person in the sample [35]. If more than 5% of the t-tests were 
significant (more specifically if the lower 95% confidence limit exceeded 5%), the scale was 
not considered unidimensional. 
6) Differential item functioning (DIF): a form of item bias that can occur when different 
groups within the sample (e.g. males and females), despite equal levels of the underlying trait, 
respond differently to an item. DIF was examined for each item with respect to age 
(dichotomised at a median of 55 years), gender and time-point (baseline or follow-up) using 
analysis of variance with a Bonferroni-adjusted alpha-level [18]. When one subgroup (e.g. 
females) consistently score differently on an item, across all levels of the trait, this is known as 
uniform DIF; when DIF varies across levels of the trait, this is known as non-uniform DIF. 
7) Targeting of the scale: assessed by comparing the mean location score for persons 
with the mean value of zero set for the difficulty of the items. For a well targeted scale, the 
mean location for persons would be close to zero, indicated by inspection of the person-item 
threshold distribution map [18,32].  
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8) Person separation reliability index (PSI): examined to assess the internal 
consistency reliability of the scale and the ability of the measure to discriminate amongst 
persons with different levels of the underlying trait. Interpretation is comparable to CronbDFK¶V
alpha coefficient where minimum values of 0.7 and 0.85 indicate acceptable reliability for group 
and individual use, respectively [32].  
Some participants in the database had completed both baseline and follow-up PBA-s 
interviews. To eliminate the possibility of time-series dependency (as some characteristics of 
the participants crossed both time-points), a sample was created so that each participant was 
only included in the data set once and each time-point was represented equally [36]. In this 
study, a total of 517 participants were included, which was optimal for Rasch analysis as larger 
samples inflate the chi-square fit statistics, which may falsely suggest misfit [37]. 
 
Results  
Sample 
A total of 822 participants obtained from Enroll-HD were eligible for inclusion in this study 
(Figure 1). The mean age of the sample was 54.7 years (range, 20.6-87.7 years) and 48.4% 
were males. Five participants were excluded due to incomplete data and 300 participants were 
excluded due to the lack of a knowledgeable informant at the baseline and annual follow-up 
interview. Of the remaining 517 participants, 266 participants were only interviewed with an 
informant at baseline and were included in the sample. 251 different participants were 
interviewed with an informant at baseline and follow-up. To eliminate time-series dependency, 
only follow-up data were included for these participants so each time-point was equally 
represented. The final sample consisted of 89 (17.2%) participants with premanifest HD and 
428 (82.8%) participants with manifest HD, within which the Total Functioning Capacity stage 
ranged from I-V. The clinical characteristics and demographics of the sample are given in Table 
2. 
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Rasch analysis 
The likelihood ratio test was significant (p<0.001) for both the frequency and severity 
dimensions of PBA-s, supporting use of the partial credit model in this study. 
 
PBA-s severity items 
Initial analysis of the 11-item PBA-s severity score revealed a non-significant chi-square item-
trait interaction VWDWLVWLFȤð=111.3, df=77, p=0.0065), indicating borderline fit to the model after 
using a Bonferroni-adjusted p-value (Table 3, Analysis 1). Summary fit residual SDs for items 
(SD=1.28) and persons (SD=0.50) were within acceptable limits. All individual item and person 
fit residuals were within ± 2.5 and individual item chi-square probabilities were non-significant.  
Inspection of the category probability curves demonstrated disordered response 
thresholds for all 11 items. The curves indicated that assessors had difficulty differentiating 
EHWZHHQUHVSRQVHFDWHJRU\³VOLJKWTXHVWLRQDEOH´DQG³PLOGSUHVHQWQRWDSUREOHP´RQ
the original five-point scale (Figure 2). However, creating a four-point scoring system for all 
items by collapsing these two response categories into a single category resulted in ordered 
thresholds for seven of the items, improving fit to the model Ȥð GI 66, p=0.059; Table 3, 
Analysis 2). This is graphically illustrated by figure 2, showing that as the level of trait increases, 
each response category in turn has a point along the level of trait when it is the most likely 
response category to be endorsed.  
Four items still displayed disordered thresholds after creating a four-point scoring 
V\VWHP+RZHYHU LWHP³DQJU\RUDJJUHVVLYHEHKDYLRXU´RQO\GLVSOD\HGPDUJLQDO disorder, 
WKHUHIRUHWKHLWHPZDVQRWGHOHWHG)RULWHP³VXLFLGDOLGHDWLRQ´LWHP³GHOXVLRQV´DQGLWHP
³KDOOXFLQDWLRQV´WKHIUHTXHQF\RIUHVSRQVHVLQFDWHJRULHVDERYH³DEVHQW´ZHUHORZZLWK
percentages of 9.40%, 5.73% and 1.83% respectively. Deletion of the three items did not 
improve model fit (Table 3, Analysis 3) and given their clinical relevance, the three items were 
also retained.  
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/RFDOGHSHQGHQF\ZDVGHWHFWHGEHWZHHQLWHP³GHSUHVVHGPRRG´DQGLWHP³VXLFLGDO
LGHDWLRQ´ ZLWh a residual correlation of r=0.14, more than 0.2 above the average residual 
correlation of r=-0.086 ,WHP ³LUULWDELOLW\´ DQG LWHP ³DQJU\RU DJJUHVVLYHEHKDYLRXU´ DOVR
displayed local dependency (r=0.17). Grouping each pair of dependent items in sub-test 
analysis accounted for the dependency between the items. The PSI decreased from 0.55 to 
0.50, but overall interpretation of the fit statistics was the same as previously. To maintain the 
integrity of the scale, none of the dependent items were removed and no further action was 
taken. Additionally, dependency can influence response thresholds, therefore the disordered 
thresholds for item 2 and item 5 may be in part due to their local dependency.  
Testing for dimensionality revealed that the proportion of significant t-tests was 5.05%, 
outside the critical value of 5.00%. However, the 95% CI lower bound was 3.00%, supporting 
the concept that the total PBA-s severity score measures a single unidimensional construct.   
No item bias (DIF) with respect to age or time-point was detected. However, significant 
uniform DIF for gender on item 1 ³GHSUHVVHGPRRG´ was detected, after applying a Bonferroni-
adjusted alpha-level (Figure 3). Inspection of the item characteristic curve revealed that item 1 
was biased towards females, indicating that despite equal levels of underlying trait, females 
were more likely to endorse the item than males. Grouping of item 1 with two other items (item 
³DQ[LHW\´ and item 6 ³DSDWK\´) displaying marginal uniform DIF (detected at a 5% alpha level) 
in subtest analysis, revealed that the DIF for gender cancelled out at the overall scale level 
[38]. Hence, no further action was taken.  
Inspection of the person-item distribution map (Figure 4) revealed that the scale was 
not well targeted (mean persons location was -2.00; SD=0.873). The easiest items to endorse 
ZHUHLWHP³LUULWDELOLW\´DQGitem ³DSDWK\´ZKHUHDVWKHPRVWGLIILFXOWLWHPVWRHQGRUVHZHUH
LWHP³GHOXVLRQV´DQGLWHP³KDOOXFLQDWLRQV´The PSI with and without extreme values were 
0.55 and 0.51 respectivelyDQGWKH&URQEDFK¶V$OSKDĮYDOXHZDVKRZHYHUWKe Alpha 
value is likely to be artificially high as it does not take targeting into account. These low values 
are likely to have been affected by the poorly targeted skewed distribution. 
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PBA-s frequency items 
The chi-square item-trait interaction statistic for the 11-item PBA-s frequency score was 
significant (Ȥð=156.26, df=77, p<0.001), indicating poor fit to the model (Table 3, Analysis 4). 
Summary and individual fit residuals and SDs for items and persons were within acceptable 
limits. However, all items displayed disordered thresholds and individual item chi-square 
probabilities were significant for three items (1, 5 and 11), indicating item misfit.  
Despite attempts at collapsing to four-point and three-point scoring systems for all 
items (based on the semantics of the original response category descriptions), the thresholds 
remained largely disordered. Ordered thresholds were only achieved for items 1,3-5, and 7 
after creating a three-point scoring system (Table 3, Analysis 5) by FROODSVLQJ³VHOGRP´DQG 
³VRPHWLPHV´VFRUHVRIDQGDQG³IUHTXHQWO\´DQG³GDLO\´VFRUHVRIDQG.  
Similar to the severity items, lRFDO GHSHQGHQF\ H[LVWHG EHWZHHQ LWHP  ³GHSUHVVHG
PRRG´DQG³VXLFLGDOLGHDWLRQ´DVZHOODVIRULWHP³LUULWDELOLW\´DQG³DQJU\RUDJJUHVVLYH
EHKDYLRXU´ 
No DIF for age, sex or time-point was detected and the scale showed no evidence of 
multidimensionality. After collapsing to a three-point scale, the chi-square item-trait interaction 
was still significant (p<0.001), the PSI with and without extremes were low (0.54 and 0.49 
respectively) and the mean persons location was -1.38 (SD = 0.83), indicating poor targeting.  
 
Discussion 
To our knowledge, this is the first study to investigate the validity of the PBA-s as a clinical 
outcome measure using Rasch analysis. The PBA-s is the recommended outcome measure 
for behavioural symptoms in HD, as it has been recognised as a reliable and valid tool using 
traditional psychometric techniques [10,15]. However, applying Rasch analysis has revealed 
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a number of limitations when using total PBA-s scores. This was demonstrated by disordered 
thresholds, local dependency, and poor targeting of the scale in this study. 
The findings of this study have shown that modifying the structure of the PBA-s 
improved its construct validity. The total PBA-s severity score demonstrated good fit to the 
Rasch model after modification to a four-point scale. However, fit to the model was not 
achieved for the total PBA-s frequency score even after reduction to a three-point scale.  
Originally, the PBA-s was created to assess neuropsychiatric symptoms individually 
and was not designed to produce a total score. However some studies have multiplied the 
severity and frequency scores for each item and subsequently added these individual item 
scores to create subscale scores [14,39]. For example, symptom clusters derived from 
previous factor analyses have led to the creation of composite affect, irritability and apathy 
subscales [1,14,15]. Broader multiplicative behaviour scores have been created using up to 
seven PBA-s items [39]. However, multiplying the raw scores together is not considered 
statistically valid due to the ordinal nature of the severity and frequency data, as multiplication 
should only be performed on ratio scale data [40]. Additionally, combining the two symptom 
dimensions contradicts the Rasch model assumption of unidimensionality, which is the concept 
that all summed items on the scale assess the same underlying construct [32]. Hence, this 
study aimed to create valid total PBA-s scores by investigating the construct validity of a total 
PBA-s severity score and separate total PBA-s frequency score. 
 
The total PBA-s severity score 
This study revealed that all 11 severity items had disordered response categories, which could 
either be the result of unclear category labels, too many response categories for a given item, 
or a combination of these factors. Given that the PBA-s asks for information from the patient, 
a knowledgeable informant and the clinical impression of the interviewer, combined with 
detailed additional category descriptions for each item [1], it is unlikely that there is ambiguity 
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between the majority of category labels. Although, ambiguity may exist semantically between 
WKH³VOLJKWTXHVWLRQDEOH´DQG³PLOGSUHVHQWQRWDSUREOHP´FDWHJRU\ODEHOVdemonstrated by 
the disordered thresholds. Therefore, this study suggests that modifying the PBA-s to a four-
point scale improves the construct validity of the total PBA-s severity score, providing a more 
robust outcome measure for clinical trials.  
Further examination of the disordered categories for items referring to rare, but 
clinically relevant symptoms of suicidal ideation, delusions and hallucinations is needed due 
to the low category response frequencies observed DERYHFDWHJRU\³DEVHQW´in this sample 
[41]. A larger or more advanced HD sample may yield a higher frequency of responses in order 
to reliably examine the response format of these items.  
Although factor analysis in previous literature has identified subscales within the PBA-
s [15], the total PBA-s severity score created in this study was deemed to be measuring a 
unidimensional construct representing the overall severity of behavioural symptoms. The 
responses for depressed mood were related to the responses for suicidal ideation and the 
same dependency was found between irritability and aggressive behaviour. Both of these 
dependencies also make sense at a conceptual level, with regard to the item content. Within 
this study, a post-hoc grouping of the dependent items was carried out, which accounted for 
the apparent dependency within this analysis. None of these items were deleted in this study 
in order to maintain the integrity of the scale, but to further improve the validity of the 
measurement construct and remove all dependency, a restructuring of the dependent items 
and their response categories may be considered. For example, creating a single depression 
item with suicidal ideation integrated into the higher scoring categories.   
Also, it was found that femalHVZHUHPRUHOLNHO\WRHQGRUVHLWHP³GHSUHVVHGPRRG´
across all levels of overall severity of behavioural symptoms, which is concordant with reports 
that the frequency of depression in women is higher in both HD and general populations [42-
44]. Although significant DIF (i.e. item bias) existed for depressed mood in this study, the 
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effects of DIF-cancellation suggested that there was no DIF for gender at the overall scale 
level, therefore the item was not deleted and the construct validity was uncompromised. 
The total PBA-s severity scale was not well targeted, as demonstrated by a lack of 
overlap between person ability and item difficulty on the person-item threshold distribution map. 
The threshold map showed clustering of persons at lower levels of the trait (i.e. floor effect) 
and gaps in the spread of both the items and persons over the range of the construct. The 
gaps and clustering in persons at lower levels of the trait provide an explanation for the low 
reliability of the scale as it fails to differentiate persons along the full range of the underlying 
trait. The mismatch in targeting suggests that additional items need to be incorporated to help 
discriminate persons at lower levels of the trait. To improve scale targeting and reliability, a 
review of the original 40-item PBA-HD [1] may provide additional items that are more likely to 
be endorsed by patients with milder behavioural symptoms, and therefore improve the scaling 
characteristics among an earlier HD population. 
The large floor effect in this study may be expected due to the nature of the study 
population. The Enroll-HD database consists of a HD population being assessed for motor, 
cognitive and behavioural symptoms, some of which may report few or no behavioural 
symptoms. Although the study sample included patients with a wide range of HD severity, 
better targeting may have been achieved in a more advanced population. However, it is 
important that the total PBA-s severity score is sensitive to changes in symptom severity early 
in disease progression, in the hope that early recognition may eventually lead to the potential 
for prevention. 
 
The total PBA-s frequency score 
Attempts to achieve fit to the Rasch model for the PBA-s frequency score were more 
problematic. Reduction to a universal three-point scale only ordered response categories for 
5 out of 11 items and fit to the model remained poor. Some of the disorder may be explained 
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by low response frequencies for ³suicidal ideation´, ³delusions´ and ³hallucinations´ items, 
however, this was not the case for other disordered items. Deletion of items with disordered 
categories was considered, but due to their clinical relevance they were retained. Again, the 
disorder may be due to ambiguous category labels or the inclusion of too many response 
categories. Although the PBA-s frequency labels are detailed, there is a degree of overlap, 
leading to some categories not being used in the manner intended by the scale developers. 
For exampleFDWHJRU\ LQFOXGHVWKHWHUP³PRVWGD\V´DQGFDWHJRU\ includes the phrase 
³DOPRVW GDLO\´ ZKLFK PD\ SUHVHQW VLJQLILFDQW FRQIXVLRQ IRU ERWK WKH UHVSRQGHQW DQG WKH
interviewer. Further amendments to the category labels needs to be considered if a total PBA-
s frequency score is to be validated as a clinical outcome measure. These results should be 
interpreted with caution as they may be due to this distinct study population. Further 
investigation is needed in other samples to support or repute the findings of this preliminary 
Rasch analysis. 
 
 
 
Limitations  
Only English speaking countries were included in this study, therefore validation of the total 
PBA-s severity score in other languages is required to enable generalisation to a truly global 
HD population. The exclusion of interviews conducted without a knowledgeable informant 
introduced sampling bias, limiting external validity in a clinical setting where this may not be 
always possible. Better targeting due to a more advanced HD sample may have been achieved 
if participants with Juvenile HD were included in the sample. Finally, the usefulness of the total 
PBA-s severity score without a corresponding total PBA-s frequency score needs to be 
considered. Restructuring the frequency items could be further explored in order to find a valid 
approach to successfully assess these two symptom dimensions together. However, the 
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relevance of frequency data could also be explored, to investigate whether attempts to 
measure frequency truly add any real information to the severity data alone. 
 
Conclusion 
Rasch analysis enabled the psychometric properties of the PBA-s to be examined in more 
detail than traditional psychometric approaches. This study highlighted important limitations of 
the PBA-s, primarily the response categories were not being used as intended and there was 
a lack of overlap between the difficulty of items and the ability of persons in this wide-ranging 
sample of HD patients. This study recommends that in its current format, the PBA-s should 
only be used to assess behavioural symptoms individually, as overall symptom scores were 
not considered to be statistically valid. However, this study found that the PBA-s severity items 
could be combined to form a valid total score measuring a unidimensional construct, with 
reduction to a four-point scale, although the mis-targeting suggests that its use as an outcome 
measure may be more appropriate in a more advanced HD population. Further research 
concerning the frequency items is needed to determine if similar limitations exist in other 
samples and to assess the influence of altering response category labels to uncover the 
potential of a total PBA-s frequency score. 
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Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Structure of the short version of the Problem Behaviours Assessment (PBA-s) 
Item Item description 
 
Severity response categories* 
1 Depressed mood 0 = absent 
2 Suicidal ideation 1 = slight, questionable 
3 Anxiety 2 = mild (present, not a problem) 
4 Irritability 3 = moderate (symptom causing problem) 
5 Angry or aggressive behaviour 4 = severe (almost intolerable for carer 
6 Apathy Frequency response categories 
7 Perseverative thinking or behaviour 0 = never/almost never 
8 Obsessive-compulsive behaviour 1 = seldom (less than once/week) 
9 Paranoid thinking or delusions 2 = sometimes (up to 4 times a week) 
10 Hallucinations 3 = frequently (most days/5, 6 or 7 times a week) 
11 Disoriented behaviour 4 = daily/almost daily for most (or all) of day 
*More detailed scoring criteria and examples exist for the severity response categories in an accompanying 
manual. 
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Table 2 
Demographics and clinical characteristics of the ENROLL-HD participants (n=517) 
Characteristic Premanifest HD 
gene-expansion 
carriers (n=89) 
Manifest HD gene-expansion carriers (n=428) 
TFC I 
(11-13) 
(n=104) 
TFC II 
(7-10) 
(n=186) 
TFC III-V  
(0-6) 
(n=138) 
Age (years) 44.6 (11.5, 20.6-70.8) 
54.0 
(13.1, 25.0-83.0) 
55.7 
(12.2, 26.1-84.3) 
60.3 
(11.6, 27.8-87.7) 
Male 33 (37%) 56 (54%) 99 (53%) 62 (45%) 
CAG repeat length 42.3 (3.0) 43.1 (2.9) 43.3 (2.8) 43.5 (3.1) 
TFC* 12.4 (1.2) 11.9 (0.8) 8.5 (1.1) 4.0 (1.7) 
Data are means (SD, range) or number (%). 
*TFC: Total Function Capacity (categories I-V), range (0-13). 
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Table 3 
Model fit statistics for PBA-s severity and frequency items 
Action Analysis Overall model 
fit 
Items fit 
residual 
Mean (SD) 
Persons fit 
residual 
Mean (SD) 
 
 
PSI 
Significant t-tests 
(%)* 
Severity items 
      
Original 1 Ȥð 111.28 
p = 0.0065 
-0.70 (1.28) -0.22 (0.50) 0.53 4.36 
Rescoring all items 2 Ȥð  
p = 0.059 
-0.67 (1.27) -0.24 (0.53) 0.55 5.05 
[95% CI 3.0-7.1%] 
Deletion of items 
2,9,10 
3 Ȥð  
p = 0.0038 
-0.32 (1.25) -0.25 (0.87) 0.53 4.14 
Frequency items 
      
Original 4 Ȥð  
p < 0.001 
-0.82 (1.25) -0.19 (0.43) 0.49 4.13 
Rescoring all items 5 Ȥð  
p < 0.001 
-0.35 (1.27) -0.17 (0.47) 0.54 4.82 
*CIs are reported when % exceeds 5%. SD: standard deviation; PSI: person separation index (with H[WUHPHVȤð
chi-square; p: probability 
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Figure Legends 
 
Fig.1. Flow diagram for the inclusion of participants+'LQGLFDWHV+XQWLQJWRQ¶VGLVHDVH. 
 
Fig. 2. 7KHFDWHJRU\SUREDELOLW\ FXUYHV IRU LWHP ³DQ[LHW\´ GLVSOD\LQJGLVRUGHUHG ILYH-point 
response categories and corrected four-point response categories. 
 
Fig. 3. Item characteristic curve displaying uniform differential item functioning for item 1 
³GHSUHVVHGPRRG´E\JHQGHU 
 
Fig. 4. The person-item threshold distribution map for the PBA-s severity items. 
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Severe 
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Severe 
Disordered 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Overall severity of behavioural symptoms Low High 
Range of disease severity assessed by items 
Easier Harder 
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Appendices 
1. The short version of the Problem Behaviours Assessment (PBA-s) 
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